XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Development revenues:        
Government contracts and other   $ 185   $ 303
Operating expenses:        
Research and development $ 1,106 327 $ 2,233 1,268
General and administrative 1,469 1,429 2,821 3,047
Total operating expenses 2,575 2,537 5,054 5,096
Loss from operations (2,575) (2,352) (5,054) (4,793)
Other income (expense):        
Interest income 4 9 8 45
Interest expense (229) (252) (476) (601)
Change in fair value of warrants   756 2 2,423
Total other income (expense) (225) 513 (466) 1,867
Net loss $ (2,800) $ (1,839) $ (5,520) $ (2,926)
Net loss per share, basic and diluted $ (0.25) $ (0.45) $ (0.56) $ (0.74)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 11,296,816 4,053,242 9,790,726 3,967,392
In Process Research and Development [Member] | Nano Tx Therapeutics [Member]        
Operating expenses:        
Research and development   $ 781   $ 781